A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2013
At a glance
- Drugs Tigecycline (Primary)
- Indications Acinetobacter infections; Enterobacter infections; Gram-negative infections; Klebsiella infections
- Focus Therapeutic Use
- 09 Oct 2007 Status changed from in progress to completed.
- 29 Sep 2005 New trial record.